Triple-negative breast cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-L1 26
• HER2 23
• PD-1 36
• BRCA1 5
• STAT3 1
• STING 0
• EGFR 4
• PI3K 1
• AKT 0
• BRCA2 2
• PARP 1
• TP53 1
• mTOR 0
• TROP2 6
• AR 1
• PTEN 0
• VEGF 4
• CDK4/6 3
• HIF-1 0
• MYC 0
• GPX4 0
• YAP 0
• CTNNB1 0
• JAK 1
• HDAC 0
• MAPK 0
• BCL-2 0
• CXCR4 1
• ERK 0
• NRF2 0
• PPAR 0
• B7-H3 4
• EZH2 0
• FAK 0
• PRMT5 0
• CD47 0
• HSP90 0
• PSMA 4
• IL-6 0
• PIK3CA 2
• CTLA-4 1
• HER3 2
• TNF 0
• COX-2 0
• IGF1R 0
• MEK 0
• FGFR 0
• MDM2 2
• MET 0
• MUC1 3
• NLRP3 0
• PALB2 0
• AMPK 0
• CD40 0
• CSF1R 1
• JNK 0
• METTL3 0
• MMP-9 0
• PKM2 0
• SIRT1 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 2,069 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

  NCT03979508· Mayo Clinic· Updated 2 Nov 2026

  “The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in first stage of study.”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  NCT06568692· Processa Pharmaceuticals· Updated 6 Oct 2026

  “Business Reason”Registry text, quoted unchanged. Source

• Suspended

  A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

  NCT06959537· M.D. Anderson Cancer Center· Updated 5 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Updated 29 Sept 2026

  “The study was terminated prematurely due to insufficient patient recruitment.”Registry text, quoted unchanged. Source

• Suspended

  ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

  NCT04638751· Persephone Biosciences· Updated 18 Sept 2026

  “Currently no funding to continue study.”Registry text, quoted unchanged. Source

• Terminated

  Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

  NCT04251533· Novartis Pharmaceuticals· Updated 10 Sept 2026

  “The study was terminated following a strategic decision to halt recruitment due to persistently slow enrollment. This decision was not driven by any new or unexpected safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

  NCT04315233· University of Utah· Updated 4 Sept 2026

  “No accrual in one year”Registry text, quoted unchanged. Source

• Terminated

  Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

  NCT05756166· Roswell Park Cancer Institute· Updated 31 Aug 2026

  “Funding ended”Registry text, quoted unchanged. Source

• Suspended

  Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

  NCT02993068· M.D. Anderson Cancer Center· Updated 26 Aug 2026

  “Accrual Limit”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

  NCT07619534· National Cancer Institute (NCI)· Source

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  NCT03424005· Hoffmann-La Roche· Source

• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

  NCT03606967· National Cancer Institute (NCI)· Source

• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Merck Sharp & Dohme LLC· Source

• Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

  NCT06802757· Shandong Cancer Hospital and Institute· Source

• A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  NCT06400472· Eli Lilly and Company· Source

• A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  NCT05852691· Hoffmann-La Roche· Source

• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

  NCT05891171· Arcus Biosciences, Inc.· Source

• Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· ECOG-ACRIN Cancer Research Group· Source

• Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

  NCT07341867· Andrew Hantel, MD· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 45
• Organoids 9
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 10
• Gene Expression Profiling 108
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 32
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 49
• Liquid Biopsy 4
• Circulating Tumor DNA 16
• Xenograft Model Antitumor Assays 254
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 34
• Machine Learning 28
• Deep Learning 15
• Cohort Studies 21
• Genome-Wide Association Study 3

See which targets of this disease your abstract mentions, and go to the people working on them.